Texas Medical Center Library

DigitalCommons@TMC
UT GSBS Dissertations and Theses (Open Access)

Graduate School of Biomedical Sciences

8-2013

Use of Echogenic Immunoliposomes for Delivery
of both Drug and Stem Cells for Inhibition of
Atheroma Progression
Ali K. Naji

Follow this and additional works at: http://digitalcommons.library.tmc.edu/utgsbs_dissertations
Part of the Medicine and Health Sciences Commons
Recommended Citation
Naji, Ali K., "Use of Echogenic Immunoliposomes for Delivery of both Drug and Stem Cells for Inhibition of Atheroma Progression"
(2013). UT GSBS Dissertations and Theses (Open Access). 382.
http://digitalcommons.library.tmc.edu/utgsbs_dissertations/382

This Thesis (MS) is brought to you for free and open access by the
Graduate School of Biomedical Sciences at DigitalCommons@TMC. It has
been accepted for inclusion in UT GSBS Dissertations and Theses (Open
Access) by an authorized administrator of DigitalCommons@TMC. For
more information, please contact laurel.sanders@library.tmc.edu.

Use of Echogenic Immunoliposomes for Delivery of both Drug and
Stem Cells for Inhibition of Atheroma Progression

A Thesis Presented to the Faculty of the University of Texas
Health Science Center at Houston
And
The University of Texas
MD Anderson Cancer Center
Graduate School of Biomedical Sciences
In Partial Fulfilment of the Requirements for the Degree of Master of Science
By
Ali K. Naji, B.S.
Houston, Texas
August 2013

II

Use of Echogenic Immunoliposomes for Delivery of both Drug and Stem Cells for
Inhibition of Atheroma Progression
By Ali K. Naji B.Sc. Advisor: Dr. Melvin E. Klegerman PhD
Background and significance: Echogenic liposomes can be used as drug and cell delivery
vehicles that reduce atheroma progression. Vascular endothelial growth factor (VEGF) is a
signal protein that induces vasculogenesis and angiogenesis. VEGF functionally induces
migration and proliferation of endothelial cells and increases intracellular vascular
permeability. VEGF activates angiogenic transduction factors through VEGF tyrosine kinase
domains in high-affinity receptors of endothelial cells. Bevacizumab is a
humanized monoclonal antibody specific for VEGF-A which was developed as an anti-tumor
agent. Often, anti-VEGF agents result in regression of existing microvessels, inhibiting tumor
growth and possibly causing tumor shrinkage with time. During atheroma progression
neovasculation in the arterial adventitia is mediated by VEGF. Therefore, bevacizumab may
be effective in inhibiting atheroma progression. Stem cells show an ability to inhibit atheroma
progression. We have previously demonstrated that monocyte derived CD-34+ stem cells that
can be delivered to atheroma by bifunctional-ELIP ( BF-ELIP) targeted to Intercellular
Adhesion Molecule-1 (ICAM-1) and CD-34. Adhesion molecules such as ICAM-1 and
vascular cell adhesion molecule-1 (VCAM-1) are expressed by endothelial cells under
inflammatory conditions. Ultrasound enhanced liposomal targeting provides a method for
stem cell delivery into atheroma and encapsulated drug release. This project is designed to
examine the ability of echogenic liposomes to deliver bevacizumab and stem cells to inhibit
atheroma progression and neovasculation with and without ultrasound in vitro and optimize
the ultrasound parameters for delivery of bevacizumab and stem cells to atheroma.
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Hypotheses: Previous studies showed that endothelial cell VEGF expression may relate to
atherosclerosis progression and atheroma formation in the cardiovascular system.
Bevacizumab-loaded ELIP will inhibit endothelial cell VEGF expression in vitro.
Bevacizumab activity can be enhanced by pulsed Doppler ultrasound treatment of BEVELIP. I will also test the hypothesis that the transwell culture system can serve as an in vitro
model for study of US-enhanced targeted delivery of stem cells to atheroma. Monocyte
preparations will serve as a source of CD34+ stem cells.
Specific Aims: Induce VEGF expression using PKA and PKC activation factors to
endothelial cell cultures and use western blot and ELISA techniques to detect the expressed
VEGF.


Characterize the relationship between endothelial cell proliferation and VEGF
expression to develop a specific EC culture based system to demonstrate BEV-ELIP
activity as an anti-VEGF agent. Design a cell-based assay for in vitro assessment of
ultrasound-enhanced bevacizumab release from echogenic liposomes.



Demonstrate ultrasound delivery enhancement of stem cells by applying different types
of liposomes on transwell EC culture using fluorescently labeled monocytes and detect
the effect on migration and attachment rate of these echogenic liposomes with and
without ultrasound in vitro.
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I. INTRODUCTION
Cardiovascular diseases are wide spread diseases that cause the highest rates of
death among humans. Atherosclerosis, also known as arteriosclerotic vascular
disease (ASVD), is a chronic arterial disease that is considered one of the most
common cardiovascular diseases (Thomas et al., 1988). Atherosclerosis is a chronic
disease that is caused by various cellular and immunological factors, which lead to
fat and cholesterol accumulation on the arterial wall. The fat and cholesterol
accumulated in the arterial wall obstruct the blood flow and cause loses of arterial
flexibility.
Atherosclerosis is a term derived from two combined Greek words: “athera”
(gruel) and “sclerosis” (stiffness). Historically, atherosclerosis was first described by
Leonardo da Vinci (1452-1519), who conducted an autopsy on an elderly man to
ascertain the cause of sudden death. He stated that “vessels in the elderly restrict the
transit of blood through thickening of the tunics”(Davies and Eollman, 1996) "In
1768, a British doctor, William Heberden, was the first doctor who described Angina
Pectoris symptoms. He indicated that patients afflicted with it are seized, but when
they walk they have the most painful and disagreeable sensation in the breast, which
seems as if it will extinguish their life if it were to increase or continue, but the
moment they stand still, all uneasiness vanishes" (Khan and Metha, 2002).
In 2006, more than 81 million Americans suffered from cardiovascular of
diseases, atherosclerosis is most prevalent (Lloyd-Jones, 2010). In the United States
1

atherosclerosis have higher mortality rates than cancer. The latest statistics indicate
that men have a higher chance of developing atherosclerosis than women in the
United States (Virmani et al, 2000). Untreated atherosclerosis can ultimately lead to
heart attacks often fatal.
A distinguishing feature of atherosclerosis is the stiffness and inflexibility of
the damaged artery due to impairment of the internal elastic lamina layer of the
arterial wall. The internal lamina which responds to blood pressure changes is
responsible for the arterial elasticity. The internal elastic lamina starts degenerating
during middle ages. However, there are many other factors that degrade the elastic
lamina such as life style, diet, genetics and stress. The arterial endothelial layer
contributes to many physiological and pathological processes. It is involved in the
regulation of vascular tone by producing a number of vasodilator and vasoconstrictor
substances that control the circulation pressure (Furchgott and Zawadski, 1980). The
factors that contribute to the development of atherosclerosis are called risk factors.
These factors contribute in initiation development of atherosclerosis via various
cellular and molecular mechanisms. (Blankenhorn and Hodis, 1993).
Atherosclerosis is generated because of the deposition of low density
lipoprotein (LDL) in the arterial wall. In atherosclerotic conditions, LDL
accumulates in the sub-endothelial matrix of the arteries (Lusis, 2000). High
circulation levels of LDL increase atheroma progression by optimizing the retention
of LDL at the sites of lesion formation. The atherosclerotic lesion can be described as
a series of changes in the histological and histochemical structure of the prone
2

region, along with the cellular matrix changes (Stary et al., 1992). This pathologic
process is mediated by enzymes such as sphingomyelinase. Atheroma is defined as a
stage after lesion formation in the affected region, in which fat and cholesterol are
accumulated on the arterial wall causing arterial swelling and stiffness (Aldons and
Lusis 2000).
Atherosclerosis is initiated due to high activities of risk factors that cause
endothelial dysfunction. Later, atheroma is generated by the development of
atherosclerotic lesions. Lesion formation is a complicated process which many
factors involves such as immunological, physiological, and cellular factors that
suppress the elastic lamina of the arterial wall. Atheroma is developed by the high
activity of the inflammation and stress signals. Atheroma progression causes many
symptoms such as hypertension and myocardial morphological changes (Assmann et
al., 2002).
High levels of LDL and other risk factors form lesions by activating
cellular and molecular factors that induce adhesion molecule expression and cellular
migration (Luscher and Barton 1997; Kinlay et al., 2001). LDL carries endogenous
cholesterol to peripheral tissues. LDL’s major components are cholesterol and
cholesteryl esters. LDL is synthesized in response to the cellular demand of
chlesterol. It is formed in liver, transported and deposited in peripheral tissues
(Assmann et al., 2002).
Apo-B 100 is the identical protein particle on the surface of LDL, which is
bound to LDL receptors on cell membranes for further digesting and restoring. The
3

LDL plays a crucial role in atheroma progression due to the involvement of
macrophages which respond to LDL accumulation in the plaque area (Kumar et al.,
2011). The digestions of LDL by macrophages cause accumulation the LDL inside
these cells and transform them to foam cells in the atheroma. Foam cell accumulation
builds the plaques lipid core plaque (Wiley, 2013).
Macrophages play a central role in the atherogenic process as modulators of
both lipid metabolism and the immune response (Kruth et al., 2002). Macrophages
accumulate cholesterol by a specific process called fluid phase endocytosis. This
process produces foam cells that depend not only on the modified LDL, but also on
macrophage activity (Kruth, 2002).
Foam cells are lipid-loaded macrophages which can be found in blood vessel
walls filled with fatty material. Macrophages are produced by monocytes
differentiation (Wiley, 2013). In atherosclerosis, foam cells are formed when the
macrophages target the fatty deposit location on the blood vessel wall (Manning,
2013). Macrophages function to digest and destroy the lipid accumulated on the
arterial wall. After targeting the fatty materials, macrophages become filled with
lipids giving them a “foamy” appearance (Kumar et al., 2010). The lipids and
lipoproteins aggregated within the tunica intima layer of arteries are oxidized by
macrophages or endothelial cell free oxygen radicals. The macrophages digest the
oxidized LDL by endocytosis via scavenger receptors, which are LDL-specific. The
oxidized LDL accumulated inside the macrophages and other phagocytes cause foam
cell formation (Berkerman, 2013). Foam cells formation represents a defense
4

mechanism to exclude cholesterol from the arterial wall. Foam cells which are small
cells that lack characteristic cell-surface markers do not cause clinical dysfunction
directly, but contribute to progression by creating the necrotic core progression
atheroma. If the fibrous cap of the atheroma eroded by the necrotic core,
the lumen of vessel ruptures, forming thrombotic embolus occluding the artery.
Endothelial function can be characterized as a balance between vascular cell
protection mechanisms and risk factors. In response to the physiological condition, a
vascular endothelial cell has the potential to be as an anti-thrombogenic. Antithrombogenic endothelial cells produce pro-inflammatory cytokines or extracellular
matrix as defensive tools. Endothelial dysfunction results from cell damage produced
by inflammatory response. The cellular dysfunction will cause an imbalance between
the protective endothelial activities and the anticoagulant properties that become prothrombotic.
Nitric oxide plays a significant role in managing the dysfunctional
progression. Endothelium dysfunction increases when nitric oxide levels drop.
Reducing nitric oxide levels will increase the oxidative stress, which is an important
promoter of the inflammatory process (Bonetti et al., 2003; Sela et al., 2002). As the
endothelial dysfunction process is initiated, it may be considered an early attribute of
atherosclerosis (Luscher, 1997).

5

Risk factors
Risk factors can be defined as factors that contribute to initiate and develop
atherosclerosis and the associated symptoms, which lead to often fatal heart attacks
and chronic strokes. These factors are hypercholesterolemia, high plasma LDL
levels, hypertension, cigarette smoking (Nicotine), age and gender (higher in male
than female), diabetes mellitus (high plasma glucose), high-fat diet, physical
inactivity, family history of premature coronary heart disease (Cayatte et al., 1994).
In the presence of cardiovascular risk factors, not all individuals develop an
arterial thrombotic process at the same level, but several additional factors can be
involved in coronary events. These additional factors can be, for instance, levels and
function of coagulation factors, local blood flow conditions (shear stress), circulating
progenitor cells and genetic factors. Inappropriate generation of thrombin may lead
to vascular occlusion (Mann et al., 2003).
Under conditions of atheroma, coagulant and anti-coagulant forces together
with pro / anti fibrinolytic substances to determine a delicate balance. Hereditary or
4acquired defects of blood clotting factors, impairment of the anti-coagulant system
or fibrinolytic mechanism, and inflammation can promote plasmatic and local hyper
coagulation state. Local thrombin generation is not only resulted in a mixed of fibrin
platelets clot, but also thrombin itself has pro-inflammatory activity. Plaque in
unstable angina possesses elevated levels of tissue factors that can be released during
inflammation, precipitating acute clinical syndromes (Matthay, 2001).
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During early stages of atherosclerotic lesion formation, leukocytes adherent
to the endothelium at particular sites in the arterial wall (Gerrity, 1981; Faggiotto et
al., 1984; Davies et al., 1988). Under inflammatory conditions, the lymphocytes
migrate across the endothelial layer and accumulate in the sub-endothelial space,
where some of the macrophages ingest LDL and form foam cells. However,
atherosclerosis appears to be a specialized inflammatory response in which leukocyte
recruitment occurs in lesion-prone areas of the arterial wall and causes lymphocyte
accumulation in the sub-endothelial matrix. This recruitment of specialized
leukocytes continues for a period of time as long as there is hypercholesterolemia.
During that time, the vascular endothelial layer remains intact and active in
recruitment of leukocytes by expression of specific leukocyte adhesion molecules.
As a result of leukocyte recruitment, a special adhesion molecule is activated to
regulate different stages of monocyte and lymphocyte migration to inflammatory
sites in a long term process (Springer and Cybulsky, 1996).
Vascular cell adhesion molecule -1 (VCAM-1) and Intercellular adhesion
molecule-1 (ICAM-1) are membrane glycoprotein that mediate the recruitment of
leukocytes in a given pathological condition. These proteins are highly expressed by
inflammatory endothelial cells. Tumor necrosis factor alpha (TNF-α) is another risk
factor that is produced by the T-cells, and it activates ICAM-1 and VCAM-1
expression in endothelial cells (Myers et al., 1992; Henseleit et al., 1994). TNF-α
along with interleukin-1 (IL-1) are inflammatory factors that trigger both ICAM-1
and VCAM-1 expressions (Wong and Dorovini-Zis, 1995).
7

VCAM-1 is an immunoglobulin-like adhesion molecule located on vascular
endothelial cells surface as membrane marker (Osborn et al., 1989). VCAM-1 binds
to alpha and beta subunits of integrins and is involved in lymphocyte and monocyte
migration. At the beginning of lesion formation, VCAM-1 is highly expressed in
atherogenesis as a stress response molecule (Chen et al., 1999).
Nitric Oxide is another remarkable factor that affects atherosclerosis
formation, which is activated by stress signals. Although NO has a variety of
functions, its most important one is to maintain vascular homeostasis. NO is a highly
diffusible inorganic radical gas with a very short half-life 3 - 6 seconds that is
synthesized by the conversion of L-arginine to L-citrulline, mediated by enzymatic
activity (nitric oxide synthase) (Moncada et al., 1991). NO mediates many biological
activities such as monocyte and leukocyte adhesion and migration through the
endothelium (De Caterina et al., 1995; Davenpeck et al., 1994).
NO also increases endothelial permeability and reduces vascular pressure,
which causes a reduction of lipoprotein flow in the vessels (Hinder et al.,
1997).Finally, NO is involved in vascular smooth muscle cell proliferation. It causes
an inhibition in smooth muscle cell proliferation and also inhibits monocyte
migration (Draijer et al., 1995; Cardona-Sanclemente and Born 1995). Reduced
endothelial nitric oxide synthase (eNOS)-derived NO bioactivity is a critical step of
atherogenesis (Palmer et al., 1987). Previous studies showed that the deficient of NO
as vasodilator in hypercholesterolemia conditions is contributed in atherosclerosis
initiation (Cooke et al., 1992). Endothelial cell types that are responsible for NO
8

production can be dysfunctional in atherosclerosis. These cells serve as an antiinflammatory factor under normal conditions (Moroi et al., 1998). Nitric oxide
synthesis is induced by the Ca2+/calmodulin-dependent activation pathway that is
mediated by NO synthase.
Nitric oxide is also produced by vascular smooth muscles cells that surround
the endothelial cells in the artery. The action of NO not only decreases the muscular
contraction of smooth muscle cells, but also activates guanylyl cyclase which
increases cellular permeability (Furchgott,F.R. Vanhoutte, 1989). NO synthesis is
activated by a high level of cAMP that associates with cellular permeability
reduction (Bredt et al., 1990; Lowenstein and Snyder, 1992). Thus Nitric Oxide plays
central role in cellular permeability regulation. All the mentioned afore risk factors
altogether participate at atherosclerosis formation and atheroma progression in
different levels and through different mechanisms.

Adhesion Molecules in Atherosclerosis:
The immune system plays a crucial role in proatherosclerosis levels and
atherosclerosis progression. The molecular mechanism of atherosclerosis can be
described as an inflammatory response by the immune system to the risk factors. The
excessive immune activities contribute to plaque formation, necrosis, and lipid
accumulation later. Different cell types are involved in this immune process by
expressing various extracellular matrixes and membrane molecules. These cells
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include smooth muscle cells, T-cells, endothelial cells, and platelets (Binder et al.,
2002; Hansson et al., 2002).
The most important anti-inflammatory molecules associated with
atherosclerosis initiation and developments are ICAM-1, P-Selectin and VCAM-1.
ICAM-1 and P-Selectin are both expressed by inflammatory endothelial cells and
they mediate neutrophil recruitment and adherence (Johnson-Tidey et al., 1994).
Smooth muscle cells also have the potential to express both ICAM-1 and VCAM-1
in the arterial wall ( Jang et al., 1994). VCAM-1 is not directly involved in
atherosclerotic lesion formation, but it significantly contributes to lesion
development and lipid core formation later (Risau and Flamme, 1995).

Figure 1. Adhesion Molecules Functions. Adhesion molecules roles in
atherosclerotic lesion formation and cell that expression of molecules (Sherer and
Shoenfeld , 2006. License No. 3199560393174 LWW publication of NCPR volume
2, No.2).
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Stem Cells and Regenerative Medicine
Stem cells undifferentiated or ‘blank’ cells that are capable of developing
many different other cells, which are later specialized to perform specific
physiological functions in organs and tissues. The majorities of the human somatic
cells are differentiated and specialized to perform defined functions in tissue, which
provides organs characteristic functions. Differentiation consists of cellular
developmental processes resulting from undifferentiated cell division in response to
appropriate conditions and signals. Furthermore, the differentiation process provides
the differentiated cell with a particular function and morphological appearance (Little
et al., 2006). The most significant properties of stem cells are a potential for selfrenewal, unspecialized cell types, and the differentiation to other types of cells that
give a specific tissue function (Rafii and Lyden 2003).

Figure 2. Stem Cell Source. Cells that are derived from differentiation of these cells.
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Stem cells can be classified based on the stages of organismal developmental.
Pluripotent stem cells that exist in embryonic stages have the potential to
differentiate to all cells types. Furthermore, they can form the progenitor cells that
are considered a source for specific types of differentiated cells in tissue such as
brain, bone, heart, and skin.
Multipotent stem cells are type of cells that exist in adults, as well as in
umbilical cords, and have less ability or strict potential to differentiate to a specific
type of cells. For instance, Multipotent stem cells found in the bone marrow that
have the potential to differentiate to red blood cells, platelets, or white blood cells,
but not into skin or brain cells (O Choi, 2006).
Stem cells hold a lot of promise in the field of regenerative medicine
providing a therapeutic approach for tissue repair and functional regeneration, in
many diseases and disorders. Stem cells offer a new look at old problems and
diseases such as burns, neurological and cardiovascular disorders, and diabetes.
Although this field is considered recent, the impact of new discoveries can
dramatically change clinical research and therapeutic approaches (Matthews, 2009).
However, stem cells in regenerative medicine face many limitations and
disadvantages, which can be summarized by:
1. Difficulty to obtain efficient and reproducible derivation stem cells that has the
ability to divide indefinitely and give rise to the specific progenitor cells type without
production of cancer cells (Lee et al., 2012).
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2. Ethical issues. Stem cells now face a many limitations, especially embryonic stem
cell research due to ethical codes and regulation policies that are considered a big
dilemma for stem cell researches progression especially embryonic stem cells
research (Borstlap et al., 2010).
3. Immunological rejection. In regenerative medicine research, immune resistance
for stem cell grafting could be another obstacle of stem cell researches.
Although recent scientific researches resolved some of these problems mentioned
above, some of these limitations are still unsolvable because of the current policies
and regulations that ban embryonic stem cells researches (Kishigami et al., 2006).
In order to progress in stem cell research and avoid the strict policies, new
methods have been invented with the use of somatic cell and nuclear transfers (cells
cloning technology)

to generate specific tissues that could only be derived

previously from embryonic stem cells. This method has potential to overcome stem
cell research challenges (Kishigami et al., 2006).

Stem Cells in Atherosclerosis
Atherosclerotic pathogenesis can be defined as endothelial dysfunction and
loss of vascular tissue function. This damage happens due to risk factors and
inflammatory activity (Ross., 1999, Blann et al., 1998). Preliminary studies showed
that transplanted stem cells give rise to neointima smooth muscle cells and functional
improvement in recipient animal vessels (Tsai et al., 2009; Hristov et al., 2008).
13

Atheroma progression depends on endothelial inflammatory mechanisms that cause
aggregation of LDL, lipids, and macrophages in the sub-endothelial layer (Bosco et
al., 2008). Many approaches to cardiovascular therapy such as revascularization
techniques, bypass and graft surgery, and coronary angioplasty, are of limited
benefits in the long term (Seiler, 2003; Barner, 2008).
Stem cells and progenitor cells have unique abilities for self-renewal and
differentiation capacity to various types of cells, providing methods for tissue
regeneration and restoral of function in many diseased organs and tissues disorders
(Rafii and Lyden, 2003). Since atherosclerosis is considered disease of endothelial
dysfunction, regenerative cell-based therapy can be an effective approach to
ameliorating atherosclerotic pathogenesis. This approach has been supported by data
obtained from animal studies. Currently, there is an uncertainty regarding
characterization of specific cell types to achieve significant therapeutic results
(Dotsenko, 2010).

Stem Cells Types Used in Atherosclerosis
Embryonic stem cells can differentiate and give rise to all cell types in the
body, however the application of these cells are often not permissible due to ethical
codes and government regulations except for some cases that have been approved by
the U.S. Food and Drug Administration (Lui et al., 2009). Adult stromal cell
reprogramming methods have recently been reported as a stem cell source for
clinical use. Fibroblasts have been commonly used in the reprogramming method to
generate induced pluripotent stem cells (IPSC). Generally, multipotent stem cells are
14

responsible for tissue repair and regeneration under normal conditions (Jaenish and
Young, 2008).
Hematopoietic and mesenchymal stem cells can be efficient types of
multipotent stem cells that have the ability to regenerate and repair cardiovascular
tissues. Hematopoietic stem cells can be obtained from many sources in the body
such as bone marrow and umbilical cords (Gallacher et al., 2000). However,
mesenchymal stem cells are mainly located in bone marrow. Also, mesenchymal
stem cells have the potential to differentiate into adipocytes, osteoblasts,
chondrocytes and myoblasts (Chamberlain et al., 2007).
Clinical experiments successfully demonstrated cardiac and vascular
regeneration using mesenchymal stem cells (Psaltis et al., 2008). Mesenchymal stem
cells have unique advantages in cardiovascular repair, such as ease of recovery, high
yield from cultures required for transplantation, low immune resistance to the cells,
and a potential to mediate vascular repair for both endothelial and smooth muscle
cells damaged by the atherosclerotic process ( Toma et al., 2002). Previous studies
showed that the tunica media in the arterial wall is the final differentiation site for
transplanted mesenchymal stem cells, giving rise to endothelial cells and smooth
muscle cells in the injured area (Babaev et al., 1990).

Mesenchymal stem cells also can differentiate to peripheral blood
mononuclear cells, which give rise to endothelial progenitor cells under the right
conditions in response to appropriate signals. Among the factors controlling
endothelial progenitor cell proliferation in vivo are hyperlipidemia, hormone levels
15

and risk factors. Low number of endothelial progenitor cells associate with
atherosclerotic lesion formations. The endothelial progenitor cells number drop in
circulation because of risk factors activity predisposing toward atheroma progression
(Xu et al., 2003; Werner et al., 2002). Therefore, a most worthwhile approach for
atheroma progression inhibition and arterial repair is to provide the circulation with
infusion appears to be endothelial progenitor cells (Xu et al., 2003).
Stem Cells Markers
Each cell type has a characteristic surface molecule that gives it special
properties and differentiates it from other cell types. Stem cells are considered
undifferentiated cells that have a special surface molecule. Stem cells have special
surface molecules called clusters of differentiation (CD). Cluster of differentiation is
a glycoprotein located on the cell surface (Lie et al., 1999). Cluster of differentiation
is considered a trans-membrane protein that is produced as a glycoprotein on the cell
membrane and plays a crucial role as signal protein on the cell surface. Also, it acts
as adhesion molecules that lead to alternative behavior or changes in the cells
function after it is activated by an external signal (Zola et al., 2006).
Cluster of differentiation can provide a feasible method to identify cells
populations and cell membrane molecules. There are more than 320 CD molecules.
Thus, cells can be classified as positive or negative for particular CD depending on
the presence or absence of each CD on the cell surface. CD has a potential of high
specific binding to specific monoclonal antibody, since it is considered a surface
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antigen. These properties can be used to detect the cells CD population (Tekstra et
al., 1996).
Generally, stem cell populations have specific CD molecules on their
surfaces that are used as identification cell markers for stem cells populations. CD34
is a special surface molecule that exists on many stem cell type surfaces and is
considered an identifying molecule of stem cell populations. CD34 plays an
important role as an adhesion of stem cells to stromal cells that lead to further tissue
regeneration by stem cells differentiation (Satterthwaite et al., 1992). CD34
molecules existence on the cell surface can provide a practical method isolating those
cells by flow cytometery to obtain a pure CD34+ stem cell population that can be
used in stem cell transplant therapy (Gulati et al., 2003).
Mesenchymal stem cells and CD34+ endothelial progenitor cells play an
important role in arterial injury therapy and it provide a reliable method for
progenitor cells numeration (Abedin et al., 2004). Clinical studies showed that early
stage atherosclerosis can be detected by decreased levels of CD34 as indication of
low vascular stem cells in circulation that essential for arterial repair (Fadini et al.,
2006). As afore mentioned, CD34 mediated stem cells adherence to stromal cells,
thus CD34 is very important particles that characterize the targeting of stem cells to
the desired injured tissues. Strong stem cell adhesion molecule binding to the
endothelial cell ligand triggers the differentiation process. Endothelial cells secrete
angiogenic growth factors that induce migration of surrounding mature endothelial
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cells to the damaged tissue, leading to activation of tissue regeneration and functional
restoration process (Urbich et al., 2005).

Figure 3. Stem Cell Types and Cluster of Differentiation. Endothelial stem cell
sources associated with surface markers and the derivative cells (Urbich and
Dimmeler, 2004. License no 3200341076041 LWW publications J Mol Cell Cardiol.
2005;39:733–742).

Therefore, this targeting and adherence of endothelial progenitor cells and
mesenchymal stem cells mediated by CD provide methods for arterial repair and
endothelial cells regenerations.
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Vascular Endothelial Growth Factor
The cardiovascular system begins to develop and become functional in very
early embryonic stages (Breier et al., 1992). The initial step is called vasculogenesis,
which generally can be described as new blood vessel formation from the
differentiation of progenitor cells (Risau and Flamme, 1995). The newly formed
blood micro-vessels develop and enlarge by recruiting more endothelial cells to
increase the vessels’ diameter in a process called "angiogenesis." Angiogenesis is
defined as new vessels development to a mature phase from pre- existing micro
vessels (Risau, 1997).
A very vital process in body growth and development angiogenesis is
responsible for blood supplies for newly grown organs and tissue repair (Folkman,
1995). Although angiogenesis is an essential process of embryonic development
under normal conditions, it may have a pathological role. Angiogenesis can be an
essential factor in many pathological conditions such as excessive cell proliferation
(hyperplasia), retinopathies, muscular degeneration, tumors and psoriasis ( Flokman,
1995; Garner, 1994). The initiation signal of angiogenesis is triggered by family
signal proteins of collectively called vascular endothelial growth factor (VEGF)
which is considered the main inducer of new blood vessel formation and growth
(Clark et al., 1998).

VEGF belongs to a family of growth factors that are synthesized as heparinbinding homodimeric glycoproteins. There are many types of VEGF that belong to
19

the same family and have a similar course of action but they perform in different
growth stages (Dvorak et al., 1995).

Table 1. VEGF Types and Functions. Types of VEGF, their functions and their
receptors (Ferrara, 2004).

Each VEGF type has various isoforms that appear to react differently with tyrosine
kinase receptors. Generally, there are three main types of VEGF receptors: VEGFR1,
VEGF2 and VEGFR3, which exist as membrane binding receptors or soluble
receptors (Fujita et al., 2008). VEGF isoforms are produced by differential mRNA
splicing (Ferrara et al., 1996). VEGF family molecules bind to tyrosine kinase
receptors on the cell surface that leads to activation of transphosphorylation
pathways. Each VEGF type has a high specificity of binding to a certain receptor,
but a common pathway (Holmes et al., 2003).

VEGF type A is the most abundant and important member of this growth
factors family. VEGF-A doe not only affects endothelial cells and angiogenesis, but
also many other cells functions such as macrophage migration, neurons, cancer cells,
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epithelial cells, and inflammatory processes (Leung et al., 2013). VEGF A is
activated by many factors that ultimately induce angiogenesis. Previous studies
showed that VEGF expression is activated in response to parathyroid and growth
hormones (Rashid et al., 2008). Many studies suggested that VEGF expression can
be activated via protein kinase pathways by different mechanisms. Angiogenesis
activated by norepinephrine is mediated by the PKC signaling pathway that induces
VEGF expression. Angiogenesis also can be activated in responce to
neurotransmitters via the PKA signaling pathway that leads to activate VEGF
expression as well (Fredriksson et al., 2000). Endogenous NO appears to enhance
vascular smooth muscle cells VEGF expression (Dulak et al., 2000).
VEGF is over-expressed under hypoxic conditions. During low oxygen
conditions, hypoxia-inducible factor 1 (HIF-1) is activated to up regulate the VEGF
gene, resulting in a high level of VEGF expression in response to low level of
oxygen (Forsythe et al., 1996). HIF-1 plays a crucial role in tumor growth inducing
VEGF-A expression, leading to angiogenesis and causing tumor growth providing a
well understanding of VEGF-A’s pathological role in cancer (Semenza,2003). Also,
VEGF receptors VEGFR1 and VEGFR2 are directly affected by hypoxia and seem
to be overexpressed under the hypoxic conditions to supply the oxygen needed by
activating angiogenesis (Gerber et al., 1997). The central roles of HIF-1 and VEGF
in progression are illustrated by the fact that HIF-1 is over expressed by v-src
oncogene action leading induction of VEGF mRNA expression (Jiang et al., 1997).
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Vascular Endothelial Growth Factor Role in Atherosclerosis
Vascular endothelial growth factor is expressed by many cells types. It was
reported that VEGF is produced by smooth muscle cells, macrophages and
endothelial cells. VEGF expression level can be varied from normal to pathological
conditions. There are many physiological and molecular changes in response to
changes VEGF concentrations (Williams et al., 1995; Berse et al., 1992; Namiki et
al., 1995).
These cell types, which are important to atheroma progression, share the
ability to express VEGF. In atherosclerotic plaques, endothelial cells, macrophages
and smooth muscle cells highly express VEGF, along with other growth factors and
cytokines that that play a crucial role in atherosclerosis progression. Many studies
reported that VEGF expression enhances atherosclerotic plaque progression (Celletti
et al., 2001). Recent studies reported that increased neovascularization is associated
with atherosclerosis (Heistad and Marcus, 1979). In advanced stages of
atherosclerosis increased vasa vasorum can be clearly observed in the arterial
adventitia due to the lack of oxygen to the atherosclerotic plaque. Vasa vasorum can
be defined as microvessels formation in the adventitial layer of the arteries (Barger
and Beeuwkes, 1990). Vasa vasorum proliferation on is activated in response to
concentrations of VEGF expressed by the damaged arteries. The neovascularization
initiated in the atherosclerotic arteries makes them most likely to be fragile and
subject to rupture, explaining how atherosclerosis can become a lethal disease
(Kamat et al., 1987).
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VEGF not only induces endothelial cell proliferation, but has also been
reported predispose the endothelial layer to development of atherosclerosis. Integrins
are trans-membrane proteins that mediate cell attachment and migration (Reynolds et
al., 2002). Previous studies of the role of α v β3 integrin in atherosclerosis showed
that these molecules regulate atherosclerosis formation indirectly by inducing VEGF
expression through phosphorylation pathways. Thus, α v β3 integrin is highly
expressed in atherosclerotic conditions (Barger et al., 1984).
It has been reported that VEGF mediates angiogenic processes by stimulating
endothelial cells to express alpha beta integrins in the atherosclerotic plaque area.
Also, it was reported that these molecules mediate smooth muscle cell attachment
and accumulation in the intima layer of atherosclerotic arteries and induce
macrophage migration and transformation to foam cells in the progression of
atheroma (Hoshiga et al., 1995).
There are some aspects of VEGF’s role in atherosclerosis that are reveals
controversial in regard to mechanism and effect. Although many studies have
reported VEGF involvement in atheroma progression through induction of
inflammatory molecules, other functions of VEGF have contradictory effects in
atherosclerotic arteries. For instance, VEGF has been shown to mediate vascular
hypotension by inducing NO synthesis, which appears to be contradictory
atherosclerosis, since is characterized by NO decrease and vascular hypertension
(Horowitz et al., 1997).
Elevated of VEGF concentration contributes to progress the lesion formation.
Since VEGF report to increase the arterial permeability, clinical data showed that
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increasing the endothelial permeability by expressed VEGF will lead to increase the
arteries stenosis that lead to LDL accumulation in the sub endothelial layer
(Sakellarios et al., 2012).

Therapeutic Approach of VEGF Inhibition
While angiogenesis is contributed in organs growth it often plays a harmful
role in many diseases. In such cases, VEGF inhibition in cancer, the is key step of
tumor progression inhibition. Formation of new blood vessels in tumor increase
tumors size because it provides essential supplement to cancer cells (Sitohy et al.,
2012).
Inhibition of VEGF expression is an efficient anti-cancer therapeutic strategy.
VEGF/ VEGFR inhibitor is a humanized monoclonal antibody that is used to inhibit
VEGF expression, leading to general inhibition of angiogenesis. In fact, monoclonal
anti VEGF antibody not only inhibits tumor neovascularization, but also inhibits preexisting vessel (Inai et al., 2004). Bevacizumab (Avastin) is one of the most effective
anti- solid tumor drugs that have been prescribed as an anti-cancer drug. It is a
humanized antibody to VEGF-A which inhibits the neovascularization causing tumor
shrinkage (Hurwitz et al., 2004). Bevacizumab is the first FDA, approved anticancer drug that acts through inhibition of angiogenesis (Ferrara, 2004) leading to
regression of existing micro vessels of the solid tumor. The US FDA approved
bevacizumab for the following clinical cases: metastatic colorectal cancer,
nonsquamous cell lung cancer, metastatic renal cell cancer, prostate cancer and
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glioblastoma (Mukherji, 2010). For intravenous administration the half-life of this
humanized antibody is 20 days (Hicklin and Ellis, 2005).
The molecular mechanism of bevacizumab can be explained by the high
binding affinity of bevcizumab to the expressed VEGF-A in the circulation. This
binding forms a complex that makes VEGF unable to bind to the VEGF receptor on
the endothelial cells membrane. Beside the bevaciamab action of trapping the VEGF
and inhibiting its activity, it also has the potential to bind to cell surface VEGF
receptors preventing unbound VEGF from binding to its receptors (Ferrara et al.,
2006; Ziemssen et al., 2009; Holash et al., 2002). (Figure 4)
Since atherosclerosis progression is mediated by VEGF expression, the
inhibition of VEGF may reduce plaque neovascularization, eliminating formation of
the high-risk atheromatic plaques. There is a suggestion of using bevacizumab as anti
VEGF to inhibit plaque formation that mediated by VEGF (Kabbinavar et al., 2003;
Hurwitz et al., 2004).
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Figure 4. Bevacizumab Action Sites: The Bevacizumab molecular mechanism and
the inhibition sites of VEGF activity in endothelial cells (Choueiri et al., 2006).

Although bevacizumab shows high efficacy in cancer therapy and other
clinical cases as anti VEGF, it has many side effects and devastating activities in the
body that limits its use as anti-VEGF therapy. The main side effects that have been
reported are hypertension, bleeding, bowel perforation, general growth regression,
hair loss and immune suppression (Sliesoriaitis and Tawfik, 2011; Vera et al., 2008).
The regular dosage of bevacizumab prescribed for cancer patients is 5 to 10
mg/kg every 2 to 3 weeks. This high dosage can cause much damage and long term
side effects which limit bevacizumab uses (Mishima et al., 2012). An efficient
delivery system can be a feasible method to reduce these side effects and optimize
drug targeting efficacy (Koukourakis and Sotiropoulou, 2011).
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Many studies are necessary before investigating the delivery and targeting
mechanisms aimed at developing nanotechnology optimizing bevaciamab efficacy
(Rai et al., 2010) while reducing its side effects.
Liposome
Liposomes are nanoparticulate pharmaceutical delivery vehicles used widely
to optimize the effectiveness and reduce the side effects of many drugs as a
therapeutic approach. Liposomes are spherical structure consisting of a bi-layer
membrane with an aqueous core (Pautot et al., 2003). They can vary in size
depending on the constituent lipid ratio from 20 nm to several um (Litzingera et al.,
1994; Pautot et al., 2003).
Liposomes can be administrated intravenously. Their half-life in the
circulation is about 15 to 30 minutes and they are eliminated by the liver (Senior,
1987). Constituent phospholipids consist of hydrophilic heads and hydrophobic tails.
In fact, phospholipid properties maintain the stability of the liposome bilayer
membrane (Kimballs, 1981) and play the major role in liposome formation.
The hydrophilic heads of the phospholipids that form the liposomal
membrane face the aqueous environment inside while the hydrophobic tails of the
phospholipids face each other in the intramembranous layer. This structure is similar
to the living cellular membrane (Dua et al., 2012).
Proteins can also be conjugated chemically to the phospholipid head groups,
especially phosphatidylethanolamine amino functions. Liposome properties of
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targeting can be characterized by the molecules attached to their surface, which
determine targeting of these molecules in the body. The liposome can be specialized
to target specific cells types because of the targeting ligands conjugated to liposomal
membranes that bind to specific surface molecules of these cells.
Often, liposomal membrane ligands can be used to enhance tissue
penetration, taking advantage of cell surface-attached molecules (Torchilin, 2006;
Rolland, 1993).
The liposomal targeting affinity to the targeted organ or tissue can be
enhanced in way that increase the effectiveness of liposomal pharmaceutical factors
and reduce the liposomal loss in the circulation. There are many methods that have
been developed to enhance and characterize the targeting and enhance the delivery
efficiency. Liposomes can be classified into many types, based on the molecules
conjugated to their membrane that characterize the liposomal targeting.
In Nanomedicine, liposomes are considered composites of molecules that are
used to deliver many compounds such as drugs, DNA, nutrient supplements and cells
(Blazs and goodbye, 2011; Medina,. 2004). (See figure 5).
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Figure 5. Liposomal Structure. Liposomal components and the possible drugs and
other molecules that can be encapsulated or conjugated to liposomes as a delivery
vehicle .

Drugs and other molecules to be delivered to the targeted sites can be encapsulated
inside the liposomes or conjugated to the liposome structure (Alkan-Onyuksel et al.,
1996). An efficient method of disassociating and releasing these molecules to the
targeted site may be required. Echogenic liposomes (ELIP) have to reflect ultrasound
because of air or other gases entrapped in them during the production processes. The
entrapped gas in ELIP causes them to serves as an ultrasound contrast (Demos et al.,
1999).
Air is usually used as entrapped gas in the liposomal membrane (Kimura et
al., 1998). The reflected pulses by the echogenic liposome cause the membrane lipid
dispersion. The dispersion of liposomal lipids breaks the membrane linkage and
composes a cavitation in the membrane leading to release the encapsulated
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components (Huang et al., 2002). The acoustic content of these liposomes can be
characterized in order to characterize the echogenic liposome activities. High
acoustic content in this echogenic liposome leads to increase the reflected pluses.
Thus, the activity will increase in response to the acoustic size increasing (Kimura et
al., 1998).
Echogenic liposomes have proven to be very efficient therapeutic delivery
agents by optimize action of drug delivery and by application of ultrasound
parameter.

Liposome Preparation
In order to prepare liposomes, different types of phospholipids and other
compounds are added together in different molar ratios to characterize the liposomal
properties. 1,2-dipalmitoyl-sn-glycero-3-phos-phoethanolamine (DPPE) ,1, 2dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), L-α-phosphatidylcholine (EPC)
,1,2-dipalmitoyl-sn-glycero-3-phosphor-rac-1-glycerol (DPPG) and cholesterol (CH)
are commercially purchased and stored in a chloroform. The polarity of the
liposomes can also be determined by choosing the proper type of phospholipids. The
liposomal bilayer membrane stability is maintained by cholesterol. In some cases,
anti-oxidants such as α-tocopherol or β-hydroxytoluidine are added to the
formulation to protect the polyunsaturated lipids.
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The afore components mentioned are diluted in chloroform s and mixed Argon is
used to evaporate remnant which is removed the chloroform completely under
vacuum. After the lipids are dried, then are rehydrated in a warm water bath and
sonicated to form the liposomes. The liposome then rehydrated with 0.32M mannitol
contained the diluted drug required to encapsulate. The mannitol’s partial dispersion
of the liposomal membrane provides a method for drugs entrapped in the liposome.
The final formulation is then frozen on dry ice and lyophilized for 24 to 48 hours and
stored at 4oC. Lyophilized ELIP are reconstituted in deionized water when need
(Buchanan et al., 2008; Huang et al., 2001).
The biggest challenge of liposome preparation is maintaining stability. There
are many factors that interfere with the chemical stability and cause liposomal
degradation or low quality liposome production. Liposomes undergo an oxidation
process or hydrolysis due to the double bond of the polyunsaturated lipids and the
phospholipid chemical properties. The double bonds of polyunsaturated lipids are
subject to oxidation and cleavage of the double bond that leads to liposomal
degradation (Kemps and Crommelin, 1988; Logaini and Davies, 1980). It is always
recommended to use high purity lipids that minimize the oxidation damage. Also, the
liposomes should be protected from light to prevent the cleavage of the double bonds
in the unsaturated lipid (Crommelin and Brommel, 1984).
Hydrolysis of liposomal lipid bonds is another challenge that is difficult to
manage because of the aqueous environment in the body where the liposomes are
injected. Hydrolysis mostly occurs in the four ester bonds present in a phospholipid
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when it is exposed to water, but the carboxyl ester bond hydrolyzes faster than the
phosphate esters bond (Kemps and Crommelin 1988). During the hydrolysis, the
hydrocarbon chains cleave from the lipid backbone, forming fatty acids and
lysophospholipids. The lysophospholipid is subjected to another hydrolysis process
in which it is the transformed to glycerophospho compound (Grit et al., 1989).
Clinical Use of liposomes present another challenge represented by immune
resistance that leading to degradation of the injected liposomes in the circulation.
This degradation will reduce liposomal efficacy and reduce the liposomal life time in
the circulation. Thus, liposomes are often coated with polyethylene glycol (PEG).
The presence of PEG on the liposomal membrane will increase the liposome
circulation time and overcome of immunological degradation. PEG reduces
liposome uptake by the lymphoreticular endothelial system (LRES) protects the
liposomes from the phagocytic uptake, thereby increasing the liposomal life time
in vivo (Immordino et al., 2006).
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II.

MATERIALS AND METHODS
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A.

Enhance Stem cell delivery conjugated to echogenic liposome by ultrasound
Overview
Many clinical studies have shown that CD 34+ stem cells hold a lot of promises in
cardiovascular disease and atheroma progression inhibition (Padfield et al., 2013).
In regenerative medicine, stem cells delivery is considered a major challenge. The
injected stem cells are subject to dispersion in the circulation or degradation by
the immune system. BF-ELIP has the ability to serve as CD34+ stem cell vehicles
having anti-CD34 antibodies and anti-ICAM-1 antibodies conjugated to the
liposomal membrane. The antibody targets ICAM-1 expressed by vascular
endothelial cells under inflammatory condition. BF-ELIP is an echogenic
liposome that can optimize targeting efficacy by exposure to ultrasound. In this
project, we will design an in vitro system that mimics atheroma conditions to
demonstrate the efficiency of the stem cell delivery methods. BF-ELIP can form a
link between CD34+ cells and endothelial cells that express ICAM-1 because of
binding of these molecules to the liposomal anti bodies. Also, we will test the
hypothesis that ultrasound application enhances both the liposome cell targeting
and delivery invitro.
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Objectives


Design a transwell culture that can serve as an in vitro system to test ultrasound
enhancement of the targeting and delivery of stem cells to atheroma.



Determine whether US enhances adherence of stem cells to transwell endothelial cell
(EC) monolayers and their passage through the monolayers using fluorescently
labeled monocytes as source of CD34+ cells.



Optimize stem cell delivery by using bifunctional liposomes and enhance the
delivery by using ultrasound application.
Experimental Design
1: a) Use a transwell system to model monocyte infiltration during atherosclerosis
b) Enhance monocyte infiltration by elevating ICAM-1 expression by TNFα.
2: Demonstrate ultrasound effect on the stem cells adherence and migration.
3: Demonstrate BF-ELIP targeting efficacy.
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Cell Culture
Human umbilical vein endothelial cells (HUVEC) (BD bioscience) are seeded
in 75cm2 flasks (Falcon) with Medium 200 (Invitrogen) supplemented with Low
Serum Growth Supplement (BD bioscience) for 3 days at 37oC and harvested with
Trypsin EDTA (sigma Aldrich). The cells are transferred to 6 transwell plates
(Corning). The 6 transwell plates are pre -incubated with endothelial cell medium
(ECM) (Invtrogen) for 30 min; 4 x 105 HUVEC are added to each insert and
incubated for 3 days at 37oC. The final ECM medium volume is 1.5 ml in the insert
and 2.4 ml in the well.
The transwell plate cell culture insert used in this project consist of
microporous polyester membrane that allows the medium and monocytes to pass
through it. The 6-well plate insert diameter is 24 mm with a growth area of 4.67 (fig
6).

Figure 6. Transwell Plate Design. The design of the Corning transwell plate and the
structure of the insert.
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Mononuclear Extraction and Labeling
Mononuclear (MNC), which cells serve as source CD34+ cells are isolated
from whole blood purchased from Gulf Coast Regional Blood Center. Buffy coats
were isolated from the blood sample by Ficoll Plus (GE Lifesciences). The MNC are
usually found in the buffy coat layer of the centrifuged blood sample (Fig 7), which
is located in the intermediate layer of the centrifuged blood sample. After gently
extracting the buffy coat layer from the centrifuged test tube, it is diluted with PBS in
a ratio of 1:2; 25 ml ficoll (density 1.077 g/ml) in 50 ml test tubes and will fill with
diluted buffy coat ill gently overlay the ficoll with an equal amount of the mixture
from above. The test tube will Centrifuge for 30 min with 700 x g without brake at 4
degree oC. The white interphase between the plasma fraction and the ficoll fraction is
transferred into a fresh tube. After washing twice with PBS the cell pellet is
resuspended with ECM medium. The cells are transferred to flask at a concentration
of 5x106 cells per ml followed by Incubation of the flask at 37Co for 1 h during
which the MNC adhere to the flask. The flask is then washed with PBS to remove
non-adherent lymphocyte and trypsinized to harvest adherent cells, which are
representing pure mononuclear culture.
Oregon Green 488 (Invitrogen) is diluted in a test tube containing PBS to
obtain 10 uM concentration. The isolated mononuclear resuspended in 10 uM
Oregon Green solution, followed by 30 min incubation at 37Co. After the incubation
period, the labeled monocyte centrifuge for 5 min and resuspended with ECM
medium protected from light.
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Figure 7. Mononuclear Cell Layers in Centrifuged Blood Sample. Centrifuged
fresh blood sample in the intermediate layer represent, buffy coat in the blood
sample.

Monolayer Treatment
On the third day of endothelial monolayer incubation in the transwell plate
insert, the HUVEC monolayer is treated with 20 nM TNFα (kindly provide by Dr.
Michael Wassler) overnight for incubation of ICAM-1 inducing. Mononuclear cells
are labeled with 10 µM Oregon Green 488 dye diluted in pre-warmed PBS described
above.
ELIP is prepared by an evaporation-rehydration-sonication-lyophilization
method. As described above, BF-ELIP are prepared by conjugating polycolonal, antihuman/ mouse CD34 antibody and monoclonal ICAM-1 antibody to ELIP using a
thioether coupling method (Herbst et al., 2010).
Pretreated HUVEC monolayers on transwell (6 wells/plate) insert membranes
are incubated with nonspecific IgG-ELIP or BF-ELIP (1mg/well) for 15 minutes at
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37Co, followed by human mononuclear labeled with Oregon Green. After adding the
labeled mononuclear, half the inserts are subjected to 6 MHz color Doppler imaging
pulses (pulse duration= 3.33 us, pulse repetition frequency= 5 kHz) ultrasound with
mechanical index (MI) = 0.4 for 5 minutes in an anechoic chamber fashioned from a
gel standoff over a rhoC rubber pad (Smith et al., 2010). (See Fig 8) .

Figure 8. Insert Exposure to Ultrasound Design. The insert is placed in a gel
standoff over a RhoC rubber pad.

The gel is cut to hold the insert while preventing the medium from leaking out. The
insert is filled with ECM medium to optimize the US application.
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Cell Harvesting
The transwell plate is incubated for 24 hr. The insert and well of the transwell
plate are then treated simultaneously with 0.25% trypsin/0.1% EDTA (SigmAldrich). The trypsinized solutions are transferred to 96 well microplatesd (Corning)
and Oregon Green 488 fluorescence is measured Spectramax M5 plate reader at an
emission wavelength of 450nm (Fig. 9).

Figure 9. Diagram of the In Vitro Transwell System Cells Harvesting. The insert
membrane has pores that allow mononuclear to migrate through the endothelial cell
layer and pass through into the well.

A standard curve is run with a series of Oregon Green-labeled MNC amount to
convert the fluorescence emission data to cell numbers.
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B. Bevacizumab Loaded ELIP Release Enhanced by Ultrasound for Atheroma
Progression
Overview
Clinical data indicates that VEGF is highly expressed in atherosclerotic
conditions. They also show that VEGF mediates atheroma progression by inducing
neovascularization in the atherosclerotic arteries while increasing the vascular
permeability, which leads to LDL accumulation and plaque formation (Celletti et al.,
2001; Sakellarios et al., 2012) . Color Doppler ultrasound has been shown to enhance
the release of bevacizumab from bevacizumab-loaded echogenic liposome, providing
a basis optimization of VEGF inhibition by bevacizumab-loaded ELIP exposed to
ultrasound. VEGF-mediated endothelial cell proliferation can be induced by phorbol
-myristate 13-acetate (PMA) and 12-deoxyphorbol 13-phenylacetate 20-acetate
(dPPA) through protein kinase activation pathways that increase VEGF mRNA
transcription (Bergslanda et al., 2004; Cai et al., 2006; Xu et al., 2007; Broughman et
al., 2006).
Thus, we hypothesize that bevacizumab can be used as anti-atherosclerotic
agent by inhibiting VEGF expression and ultrasound that can be used to enhance the
release of bevacizumab from bevacizumab-loaded ELIP to optimize the inhibition. In
this project we will demonstrate the efficiency of liposomes for both cellular delivery
and drug release to inhibit the atheroma progression. In this project we will
demonstrate the efficiency of ELIP for both stem cell delivery and drug release to
inhibit atheroma progression.
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Objectives


Induce VEGF expression by using an independent activator in HUVEC cell cultures,
detectable by western blot of the cellular extracts.



Design VEGF ELISA to determine VEGF expression in HUVEC cell culture and
demonstrate bevacizumab inhibition of VEGF expression in vitro.



Design a proliferation assay to demonstrate the relationship between the endothelial
cell proliferations mediated by VEGF expression for the purpose of demonstrating
bevacizumab-loaded liposome (BEV-ELIP) inhibition efficacy of HUVEC
proliferation mediated by VEGF.



Demonstrate BEV-ELIP efficacy to inhibit VEGF expression and determine
ultrasound effect on the bevacizumab release enhancement from the loaded liposome
in both the VEGF ELISA and proliferation assays.
This project was conducted in Dr. Klegerman’s lab as an in vitro model for the
inhibition efficacy of bevacizumab/BEV-ELIP of atheroma progression mediated by
VEGF.
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Experimental design


Induce PKA, and PKC, mediated VEGF expression by PMA/DOPPA as protein
kinase activators.



Design cell proliferation assay for control and treated groups to characterize the
relationship between cell proliferation mediated by VEGF and inhibition by
Bevacizumab/BEV-ELIP.



Use Western blot to detect VEGF expression and PKC/PKA activation
(translocation) in control and treated groups.



Design VEGF ELISA for control and treated groups to determine VEGF expression
level and inhibition efficacy of Bevcizumab/BEV-ELIP.



Determine ultrasound enhancement of BEV-ELIP release by both VEGF ELISA and
proliferation assay on HUVEC cells.
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Cell Culture
Human umbilical vein endothelial cells (HUVEC) (BD bioscience) are seeded
in 75cm2 flasks (falcon) with Medium 200 (Invitrogen) supplemented with Low
Serum Growth Supplement (BD bioscience) for 3 days at 37oC in an tuner place of
5% CO2. HUVEC are trypsinized with 0.25% trypsin/0.1% EDTA (Sigma-Aldrich).
The harvested HUVEC are transferred and seeded into 24-well plates (Falcon) with
Medium 200 (8x 104 cells per well).
The seeded cells are incubated overnight after which the plate is divided into
three separate groups. The first group is treated with 10nM of phorbol 12-myristate
13-acetate (PMA) (Sigma-Aldrich). The second group is treated with 100 nM 12deoxyphorbol 13-O-phenylacetate (DOPPA) (Sigma- Aldrich), while the third group
is left untreated as a control group. The plate is incubated for 12 hours and harvested
after 12 hours of treatment and approximately 30 hr. of total incubation.

44

BEV-ELIP Preparation
Bevacizumab loaded ELIP can be prepared by adding the following
components (molar ratio) to round bottom flask (provided by Dr. T Peng):
Dipalmitoylphosphatidylcholine (46%) ; Dioleoylphosphatidylcholine (23%);
Dipalmitoylphosphatidylglycerol (8%); Dipalmitoylphosphatidylethanolamine (8%);
Cholesterol (15%).
After mixing the components, the flask is rotated in a warm water bath and
evaporated under a stream of Argon. The flask is then placed in a vacuum desiccator
connected to a pump overnight for complete durations after which the flask contents
are rehydrated with 0.2M D-mannitol (Fisher Scientific) containing 5 mg/ml of
Bevacizumab (Genetech). After through mixing BEV-ELIP, the flask then will kept
overnight in low temperature air vacuum (lyophillizaition) and rehydrated with water
next day transferred to small vial as its ready to use.
To expose The BEV-ELIP to ultrasound ,BEV-ELIP contained in rubber condom
evacuated from the trapped air and submerged in water bath and exposed to
ultrasound for 5 min (30 sec off/on) for bevacizumab release followed by UV
exposure for 30 to 60 min for sterilization. The ultrasound set for a parameter of 6
MHz color Doppler imaging pulses (pulse duration= 3.33 us, pulse repetition
frequency= 5 kHz) ultrasound with mechanical index (MI) = 0.4 for 5 minutes in an
anechoic chamber fashioned from a gel standoff over a rhoC rubber pad (Smith et al.,
2010).
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Protein Preparation and Western Blotting
Three groups of HUVEC seeded in 24 well plates (untreated or incubated
with 10 nM PMA or 100 nM DOPPA) are placed on ice and homogenized on
homogenization buffer for resuspending and collecting .The homogenization buffer
consists of 50mM Tris HCl, pH 7.5 with 0.5 uM EDTA, 0.5 mM EGTA, 10%
glycerol, 10 ug of both inhibitor A and inhibitor B that has 0.2 nM fluoride
associated with 50mM of Triton 100X detergent (all provided by Dr. E. Martin).
For detection of VEGF expression total proteins isolated from HUVEC.
Briefly, micro plates wells are washed with phosphate buffer solution, pH 7.4
(Hyclon co.), followed by 100 ul of homogenization buffer, freezing the plate for 30
min at -80 OC. After freezing the sample collected from each group placed in small
vials. Samples are then lysed by rapid freeze-thaw cycles using dry ice of three
repetitious followed by centrifugation at low temperature (0 oC) for 10 min at 14000
RPM. The pellet is discarded and the protein contained in the supernatant.
To investigate the mechanism of VEGF expression mediated by PKC and
PKA pathways, western blots for PKA and PKC are run in order to determine the
translocation of the protein kinases for the cytosol to the endoplasmic reticulum
membrane in response to VEGF activation factors.
PKC and PKA can be extracted from the cytosol and the membrane fraction
using protein fraction methods. The three groups of HUVEC washed with PBS are
placed on ice, followed by add on of 100ul homogenization buffer. Samples were
lysed by freeze-thaw cycles (3X) in dry ice and water at room temperature. The vials
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are centrifuged at 100,000X g for 1hr.The supernatant represents the cytosolic
protein which is then removed to new vials while the pellet is resuspended with 1 M
NaCl in cold homogenization buffer followed by centrifugation for 30 min at
100,000X g. The supernatant is discarded and the pellet dissolved in homogenization
buffer containing 2% Triton X100. The dissolved pellet represents the membrane
protein while the supernatant extracted at the beginning represent the cytosolic
protein.
Bradford Protein Assay
Following cell harvest with lysis homogenization buffer, the protein
concentration of each sample is determined by the Bradford technique. Bovine serum
albumin (BSA) (provided by Ms. E. Golunski) is used to construct protein standards
ranging from 200 to1000 ug/μL. The homogenized samples are diluted as needed and
triplicate determinations were made by pipetting 5μL of sample into 100 ul of
distilled water in a microplate. The absorbance of the plate is measured at 595 nm in
a Spectromax M5 plate reader. The protein concentration of the unknown sample
was determined using a standard curve of BSA concentrations verses the
absorbance.
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Western Blot
One volume of homogenized protein is added to three volumes of loading
buffer (provided by Ms. E. Golunski) and denatured at 90oC for 5 min. The
denatured samples are added to 12% acrylamide gel. Protein bands in SDS-PAGE
gels are transferred to nitrocellulose membranes, which are then incubated with a
100X dilution of primary antibody ( bevacizumab kindly provided by Dr.
Klegerman), washed and followed by 4000X secondary IgG antibody anti-human
(IRDye 800CW, Sigma Aldrich ). Human VEGF standard is run on the same gel
.The primary and secondary antibody are diluted in Li-Cor Odessy blocking buffer
(Bioscience) provided by (Dr. T Peng). The nitrocellulose membrane is assayed for
infrared florescence with a Li-Cor Odyssey instrument.
For PKCα, the nitrocellulose membrane is incubated with Primary antibody:
1 µg/ml anti-PKCα (Cell Signal) followed by 4,000X anti-rabbit secondary antibody
(IRDye 800CW, Sigma Aldrich). For PKAα, the membrane is incubated with
primary antibody of 1 ug/ml anti PKAα (Santacluz) followed by 4000X of anti-rabbit
secondary antibody (IRDye 800CW, Sigma Aldrich). The membrane is incubated
overnight with the primary antibody at 4oC, followed by 1 hour of secondary
antibody. Protein bands are detected was with the Odyssey LI-COR IR fluorescence
imaging system.
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VEGF ELISA
VEGF expression can be detected in vitro by VEGF ELISA of cultured
endothelial cells in microplate wells. The ELISA is performed by seeding 2 x 104
HUVEC in 96-well microplate wells incubated overnight with Medium 200. After
12 hours of incubation, 10 nM PMA or 100 nM DOPPA is added to the treated
groups.
After 30 hours of total incubation, cells are fixed with formalin (Sigma
Aldrich) and incubated with 5 µg/ml of bevacizumab (primary antibody) for 2 hours
at 37oC. Wells are washed with PBS for 3 times, followed by 10,000X secondary
anti-human IgG-HRP (Sigma Aldrich) for 1 hour at room temperature. After wells a
3X PBS washes for three time color development with is pretreated ABTS substrate
is for 30 minutes at room temperature. Plate absorbance is measured at 405 nm with
a SpectraMax M5 reader.
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Proliferation Assay
The endothelial proliferation can be characterized by VEGF expression and
bevacizumab inhibition. The proliferation assay is used to investigate the relationship
between VEGF expression and cell proliferation. Fresh HUVEC are added to 96well plates 2 X 104/well and incubated for 18 hours in Medium 200. The wells
treated with 10 nM phorbol 12-myristate 13-acetate (PMA), 100 nM 12deoxyphorbol 13-O-phenylacetate (DOPPA) or medium alone (no PMA, no
DOPPA) 4 hours later and incubated for 24 hours.
The wells either have the medium alone, bevacizumab or BEV-ELIP added to
control groups or to groups pretreated with PMA/DOPPA. After the final incubation,
cells are enumerated by trypsinization and counting with a hemacytometer.
Colorimetric assay can be used to obtain accurate results for many groups. This assay
can be done by adding 10 ul (3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium
bromide (MTT assay, Sigma Aldrich) to 100 ul of wellplate medium incubated for
four hours. After this incubation, 75 ul of medium is gently removed and 25 ul of
DMSO is added to each well, followed by 1 hr. of incubation 37oC. Absorbance of
the wells is measured by a SpectraMax M5 reader at 540nm.
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III.

RESULTS AND DISCUSSION
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A. Enhance Stem Cell Delivery Conjugated to EchogenicLiposome by
Ultrasound
The in vitro transwell system estimated through the labeled monocyte
adherence and migration endothelial monolayer. Based on the growth area of the
insert provided by the transwell manual, 400,000 of HUVEC added to the insert can
pass through the membrane without obstacles (See Fig10).

Figure 10. HUVEC Number and Mononuclear Adherence and Migration Rate.
The labeled mononuclear migration and adherence varied with different HUVEC
numbers, 400,000 cultured HUVEC in the insert gives the highest number of
migrated mononuclear (well), a good adherence rate (insert) and the lowest rate of
mononuclear loss generally. The added mononuclear are700,000,each point
represents a (mean+ SD, n= 6.)

After we tested the HUVEC number that provides a confluent monolayer
giving the highest total control mononuclear number adherent to and passing through
the monolayer, we then induced the expression of ICAM-1 as an inflammatory
signal. TNFα upregulates ICAM-1 expression by endothelial cells, providing method
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to characterize the atherosclerotic condition invitro (Bernot et al., 2005). Endothelial
permeability increases in response to increasing TNFα concentration (Watsky et al.,
1996). TNFα causes an reduction in the density of the endothelial monolayer and
increases its permeability in vitro (Friedl et al., 2002). In these studies, a series of
TNFα concentrations was added to the endothelial monolayer to optimize ICAM-1
expression, while limiting cell death (Fig. 11).
A

B

Figure 11. TNFα Concentration Dependence of Mononuclear Adherence and
Migration. A: Monocyte migration (wells) and adherence (insert) in response to a
series of TNFα concentrations, 10nM TNFα gives the highest total monocyte number
(adherence and migrated mononuclear, each point us the mean of determinations +
SD 4). B: Standard curve of Oregon Green fluorescence intensity vs. mononuclear
cell number. The added mononuclear is 700,000.
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The optimal total mononuclear number detected in both well and the insert by
seeding that can be obtained at 400,000 of HUVEC and adding 10nM TNFα to the
transwell plate. We used this optimized system to demonstrate bifunctional ELIP
efficacy compared to a control preparation (IgG-ELIP) in addition to untreated
HUVEC. We also assessed the effect of ultrasound on the study groups (Fig.12).
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A

B

Figure 12. BF-ELIP Efficacy with and without Ultrasound. A Ultrasound greatly
enhanced the mononuclear adherence to the endothelial monolayer and the migration
level through the monolayer in all exposed groups. Mononuclear 700,000, mean+
SD; n=6. B Proportion of mononuclear passing through the HUVEC monolayer;
Mean ± SD, n=6.
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BF-ELIP enhanced adherence of mononuclear to the ICAM-1expressing
HUVEC monolayer relative to untreated controls and IgG-ELIP, but did not increase
the number of monocytes traversing the monolayer. The monolayer was treated with
10nM of TNFα overnight to express ICAM-1. US greatly increased the number of
monocytes adhering to and passing through the monolayer in all groups. The greatest
increase of monocytes passing through the monolayer was without ELIP, but only
BF-ELIP caused an increase in the proportion of monocytes passing through the
monolayer
B. Bevacizumab Loaded ELIP Release Enhanced by Ultrasound for Atheroma
Progression
The MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)
assay was used to provide evidence that induced VEGF could mediate HUVEC
proliferation. The expressed VEGF can also be detected by VEGF ELISA using
bevacizumab as anti-VEGF antibody. It has previously been shown that VEGF
expression is mediated by PKC and PKA. Thus, phorbol -myristate 13-acetate
(PMA) and 12-deoxyphorbol 13-phenylacetate 20-acetate (dPPA) activators of PKA
and PKC will induce VEGF expression, which is by the protein kinase pathways that
stimulate VEGF mRNA transcription. These two activators could be toxic at high
concentrations, so it is necessary to determine the optimal concentrations of dPPA
and PMA that induce the highest HUVEC cell proliferation rate without appreciable
cell death. (Fig. 13).
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A

B

C

Figure 13. Proliferation Assay for PMA and dPPA. The MTT assay was used to
detect cell proliferation. A: The highest proliferation rate can be obtained when
HUVEC were treated with 10nM of PMA compared to series of PMA
concentrations, (curve = Mean ± SD;n=4;*P<0.01 vs Control , †P<0.05 vs. 50nM
PMA).B: The highest proliferation rate can be obtained when HUVEC treated with
100nM of dPPA compared to series of dPPA concentrations started as non-treated
cells (control) and 500 nM as highest concentration. (Curve = mean ± SD; n = 4.* p
< 0.01 vs. Control; † p < 0.01 vs. 50nM dPPA). C: MTT assay standard curve.
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The fig. 13 also shows that cell proliferation is induced by protein kinase
activators via protein kinase pathways. To prove the hypothesis that VEGF mediates
protein kinase-induced cell proliferation, the VEGF ELISA was used to detect VEGF
expression in response to protein kinase activators. The optimal concentrations of PK
activators determined above that gave the highest proliferation rate were added to
HUVEC microplate, followed by anti-VEGF and secondary anti body treatment
(Fig14).
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A

B

Figure 14. VEGF ELISA for PMA and dPPA. A. VEGF expression level of
HUVEC treated with PMA and the optical density in response to the primaty
antibody concentration increasing compared to control. B. VEGF expression levels
in response various dPPA concentions compared to control (Curve= mean+ SD,
n=4).

The results obtained from the VEGF ELISA support the hypothesis that
VEGF mediates cells prolifertion caused by activation of protein kinase pathways.
The ELISA respouse was optimized relative to primary and secondary antibody
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concentrations. The binding of bevacimab increased in response to prior exposure of
increasing bevacizumab concentrations, reflected byincreasing OD values. High
concentration of dPPA led to inibited cell proliferation and declining VEGF
expression because of the toxic effects of dPPA at high concentrations.
Cells pre-treatment with bevacizumab or bevacizumab-loaded ELIP inhibited
both cell proliferation and VEGF expression. The induced VEGF expression by
protein kinase activators was blocked by bevacizumab or BEV-ELIP .The inhibition
of both VEGF expression and cell proliferation varied based on the pretreatment
concentration of bevacizumab ,BEV-ELIP (Fig.15).

Figure 15. VEGF ELISA for Bevacizumab/BEV-ELIP Inhibition.VEGF
inhibition increased by increasing the concentration of bevacizumab,BEV-ELIP.
The ELISA indcated that BEV-ELIP inhibition efficacy is greater than bevacizumab
alone. (Cuve= mean + SD; n=4)
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Liposoma exposure to ultrasound increases the release of bevacizumab from the
loaded ELIP, which increases the VEGF ihibition and cell proliferation in vitro
demonstrated by VEGF ELISA and MTTassay (Fig. 16).
A

B

Figure 16. Ultrasound Enhancement of BEV-ELIP Inhibtion. A.VEGF ELISA
showed that the optimal ihibition of VEGF expression can be observed with BEVELIP exposure to ultrasound prior to treatment. Bars = Mean ± SD;* P<0.01 vs
Control, *P<0.01 vs BEV without US .B: The proliferation assay shows that prior
BEV-ELIP exposure to ultrasound caused the highest proliferation ihibition. Curve
= Mean ± SD;n=4;*P<0.01 vs Control , †P<0.01 vs. BEV with US.
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VEGF expression induced by PMA can also be detected in cell homogenates
by western blot technique. Transposed SDS electrophoretogram was incubated with
bevacizumab as primary anti-body for VEGF detection (Fig. 17).
A

B

Figure 17. Western Blot for VEGF Expression. A. VEGF expression was induced
by 10nM PMA compared to control in which no VEGF was detected. B: Bars
represent the ratio of detected VEGF band intensity divided by total protein band
(B.actin).
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To demonstrate that PMA and dPPA activate VEGF expression via protein
kinase pathway, western blot were ran on protein fraction homogenates for both
cytosolic and membrane lysis protein (Fig. 18).
A

B

C

Figure 18. Western Blot for PKCα Translocation. A. PMA and dPPA induce
VEGF expression by Protein Kinase C alpha translocation from the cytosolic to the
endoplasmic. PKCα located in the cytosol the none active form of Protein Kinase C.
B: Bars represent the ratio of detected PKC band intensity divided by total protein
band (B.actin).,* P<0.01 vs corresponding control, ϯ P< 0.01 vs. corresponding
control, C: ERP72 protein detection for the same SDS page.
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ERP72 is an endoplasmic reticulum protein. The detection of this protein in
western blots provides evidence that the PKCα homogenates of cells pretreated with
PMA and dPPA was located in the endoplasmic reticulum indicating protein kinase
C activation.
To prove the hypothesis that VEGF expression can be induced by any activation of
protein kinase C or A,
HUVEC pre-treated with 30uM forskolin (cellsignals Co.) for 1 hour after 12
hours of primary incubation were subjected to cell homogenization and protein
fractionation for western blot. See fig (19).
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A

B

C

Figure 19. Western Blot for PKAα and VEGF Expression. A. PKA expression in
pre-treated cells with 30uM forskolin compared to non-treated group. B: The ratio of
detected PKA percentage to the total protein (beta actin). C: VEGF expression by
forskolin via PKA activation.
Forskolin is a direct activator of PKAα mediated by cyclic AMP. Fig. 19
confirms that Forskolin induces PKA expression. In response to this activation
forskolin induce VEGF expression via PKA activation pathway supporting the
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hypothesis that VEGF expression could be mediated by any activation of PKA
alone.
IV. Discussion
Stem cells have been used previously for vascular regeneration. Atherosclerosis has
been defined as arterial cell dysfunction (Luscher, 1997; Kinlay et al., 2001) and can
be managed using endothelial progenitor cells. Although using stem cells for
vascular regeneration is considered a useful therapeutic approach, it has many
limitations (Xu et al., 2003). Stem cells delivery was been a big challenge of vascular
regeneration therapy. Using efficient delivery methods such as liposomes provides a
feasible method to manage the cellular delivery to the damaged area. We have
demonstrated the efficacy of bifunctional liposomes for cellular delivery of stem
cells to reduce the atheroma progression (Herbt et al., 2010). Previous studies have
shown that bifucntional liposomes reduce stem cells loss and increase stem cells
adherence to the endothelial monolayer in vitro.
Treating HUVEC with TNFα simulated the inflammatory conditions
associated with atheroma progression that leads to endothelial dysfunction. The
TNFα induced I-CAM-1 that is an inflammatory molecule associated with
atherosclerosis progression and thus provides plausible target for bifunctional
liposome targeting. BF-ELIP has anti ICAM-1 antibody conjugated to the liposomal
membrane. The BF-ELIP mediates stem cell adherence to the inflamed endothelial
cells. Ultrasound plays a crucial role in stem cell delivery mediated by BF-ELIP. The
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results of this project indicated that groups exposed to ultrasound had a higher rate of
stem cell migration and adherence.
To understand the role of ultrasound in BF-ELIP targeting enhancement
,previous experiments indicated that ultrasound increased the endothelial
permeability by causing temporary disruption of the cellular membrane that makes
the delivered component to stream through .The membrane disruption results from
the ultrasonic contrast agent that effect on the acoustic components of the cellular
membrane causing the intracellular molecules porosity that lead to increase the
endothelial permeability.Also intrasound pulses causing proposity in the intracellular
matrix Therefore, the migration rate of stem cells is increased due to high
permeability endothelial layer exposed to ultrasonic pulses. (Juffermans et al., 2003).
Ultrasound also enhances stem cells adherence. The results of this study
indicate that all stem cells samples exposed to ultrasound pulses had a very high rate
of adherence to the endothelial monolayer supporting the hypothesis that ultrasound
enhances cellular delivery. The contrast ultrasound pulses induce the mononuclear
cells pass through and adherent to the endothelial monolayer and it can be optimized
by liposomal delivery to the endothelial layer.
Bifunctional ELIP promotes enhanced stem cell adherence with and without
ultrasound e because of the conjugated of ICAM-1 antibody which binds to
endothelial ICAM-1 that is expressed under inflammatory conditions.
Future work following this project will focus on demonstration of efficacy in
vivo since the hypothesis of this project has been supported in-vitro. Further
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investigation is also needed regrading mechanism of stem cell adherence enhanced
by ultrasound. We also need to investigate the mechanisms of ultrasound mediated
the increased cellular permeability and stem cells passage.
Angiogenesis in atherosclerotic arteries is mediated by VEGF. Cell
proliferation can be induced by many intracellular pathways. VEGF-induced cellular
proliferation can be inhibited by bevacizumab. Although bevacizumab is approved
for tumour growth inhibition through blocking of VEGF activity, but it has
devastating side effects. PMA and dPPA have been used to induce VEGF expression
in vitro through stimulation of Protein Kinase A and C.
Treating cells with high concentrations of these components over time will
cause to cells apoptosis and to activation of protease that cause cell proliferation
regression (Park et al., 2001).
Therefore, these components were titrated to determine the optimal concentration for
mediating cell proliferation with minimal toxicity. The dual cellular treatment with
protein kinase activators and bevaciamab as VEGF blocker will severely inhibits cell
proliferation because bevaciamab blocked VEGF activity while the protein kinase
activator as general activator induce another pathways protease activity.
Protein kinase A and C mediates VEGF expression when they translocate
from the cytoplasm to the endoplasmic reticulum. The translocated PKA and PKC
alpha type will lead to induction VEGF expression by increasing VEGF mRNA
synthesis (Mamputu et al., 2002).
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Forskolin has been used to investigate the relationship between VEGF
expression and PKA activation alone. Forskolin is considered a Protein Kinase A
activator through the cAMP signalling pathway. Short period of treatment with
foskolin led to VEGF expression mediated by protein kinase A. Activation of either
PKC or PKA is sufficient to induce VEGF expression whether the protein kinase is
translocated or not. Thus, forskolin shows that activation of PKA alone is sufficient
to induce VEGF expression with no needs for both PKA and PKC.
It is expected that liposomes will provide a method to reduce bevacizumab
side effects, while affording a controlled release formulation for delivery of the drug
This project demonstarted that ultrasound enhanced the liposomal release of
bevacizumab optimizing VEGF inhibition. The liposomal release enhancement by
ultrasound is caused by the cavitation effects of ultrasound pulses. That disrupt the
lipid bilayers realeasing the encapsulated bevacizumab.Ultrasonic pulses are also
responsible for increasing the endothelial permeability by disrupting the extracellular
matrix and induce the porosity of cellular membrane and the intracellular molecules
in endothelial cells that lea in the end to increase the drug uptake by the cell
(Juffermans et al., 2009; Cho et al., 2002).
Thus, the results obtained with cell based assay provided enough evidences to
demonstrate BEV-ELIP efficacy with and without ultrasound in vitro.Furthermore,
the results obtained in this project showed that even a low concentration of BEVELIP inhibits VEGF expression instead of using a high concentration of
bevacizumab to reach the same inhibition rate.
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Thus, a low dose of bevacizumab released from ELIP by ultrasound can
achieve the same effect as a high concentration of bevaciamab alone with fewer side
effects.
As future steps of this work, as vivo investigation is required to demonstrate
the efficacy of BEV-ELIP enhanced by ultrasound to reduce atheroma progression in
an animal model as part of translational development of a therapeutic approach for
bevacizumab-mediated pathway to reduce atheroma progression in the clinic.
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